Vistagen Therapeutics Files 8-K
Ticker: VTGN · Form: 8-K · Filed: Jul 10, 2024 · CIK: 1411685
| Field | Detail |
|---|---|
| Company | Vistagen Therapeutics, Inc. (VTGN) |
| Form Type | 8-K |
| Filed Date | Jul 10, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, filing, corporate-event
Related Tickers: VTGN
TL;DR
VTGN filed an 8-K on July 10th for events on July 9th, likely financial or corporate updates.
AI Summary
Vistagen Therapeutics, Inc. filed an 8-K on July 10, 2024, reporting an event that occurred on July 9, 2024. The filing pertains to financial statements and exhibits, and other events, but does not specify the exact nature of these events or any associated financial figures within the provided text.
Why It Matters
This filing indicates Vistagen Therapeutics is providing updated information to the SEC, which could include significant corporate events or financial disclosures relevant to investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting events and exhibits, with no immediate indication of negative news or significant financial distress.
Key Players & Entities
- Vistagen Therapeutics, Inc. (company) — Registrant
- 0001411685 (company) — Central Index Key
- 20240710 (date) — Filing Date
- July 9, 2024 (date) — Earliest Event Reported
FAQ
What specific 'Other Events' are being reported by Vistagen Therapeutics in this 8-K filing?
The provided text for the 8-K filing lists 'Other Events' as an item information, but does not specify the details of these events.
What financial statements or exhibits are included with this 8-K filing?
The filing indicates 'Financial Statements and Exhibits' are included, but the specific contents are not detailed in the provided text.
When was Vistagen Therapeutics, Inc. incorporated, and in which jurisdiction?
Vistagen Therapeutics, Inc. was incorporated in Nevada, as indicated by the filing.
What is Vistagen Therapeutics' principal executive office address?
The principal executive offices of Vistagen Therapeutics are located at 343 Allerton Ave., South San Francisco, California 94080.
Has Vistagen Therapeutics, Inc. had any previous names?
Yes, Vistagen Therapeutics, Inc. was formerly known as VistaGen Therapeutics, Inc. (name change on 20110610) and Excaliber Enterprises, Ltd. (name change on 20070906).
Filing Stats: 480 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-07-10 16:34:14
Key Financial Figures
- $0.001 — ch registered Common Stock , par value $0.001 per share VTGN Nasdaq Capital Market
Filing Documents
- vtgn20240710_8k.htm (8-K) — 23KB
- ex_696954.htm (EX-99.1) — 15KB
- a01.jpg (GRAPHIC) — 6KB
- 0001437749-24-022484.txt ( ) — 180KB
- vtgn-20240709.xsd (EX-101.SCH) — 3KB
- vtgn-20240709_def.xml (EX-101.DEF) — 11KB
- vtgn-20240709_lab.xml (EX-101.LAB) — 15KB
- vtgn-20240709_pre.xml (EX-101.PRE) — 11KB
- vtgn20240710_8k_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. On July 9, 2024, Vistagen Therapeutics, Inc. (the " Company ") announced the broadening of its global intellectual property portfolio after receiving multiple new patents related to the use of PH80 for the treatment of migraine. PH80 is the Company's non-systemic, hormone-free investigational pherine nasal spray in development as a rapid-onset treatment for vasomotor symptoms (hot flashes) due to menopause, with the potential to also treat premenstrual dysphoric disorder, dysmenorrhea, and migraine. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits . (d)Exhibits Index Exhibit No. Description 99.1 Press Release issued by Vistagen Therapeutics, Inc., dated July 9, 2024, furnished herewith. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Vistagen Therapeutics, Inc. Date: July 10, 2024 By: /s/ Shawn K. Singh Shawn K. Singh Chief Executive Officer